Wegovy on PubMed: what the published research tells you

You found the STEP 1 paper, here's how to read what it says

You're on PubMed, looking at the STEP 1 trial, published in the New England Journal of Medicine. The study randomised 1,961 adults with a BMI of 30 or above (or 27 or above with at least one weight-related condition) to either weekly semaglutide 2.4mg or placebo, alongside counselling on diet and activity. At 68 weeks, the semaglutide group had lost an average of about 15% of their starting body weight; the placebo group lost roughly 2.4%.

A common misconception worth clearing up gently: many people assume the trial participants were on semaglutide alone, with nothing else changing. They weren't. All participants received structured lifestyle support. The medicine's effect is measured on top of that baseline. That matters when you're interpreting whether a result from a clinical trial is likely to translate to your own situation.

The trial also reported on the proportion of participants achieving clinically meaningful thresholds: around 69% of the semaglutide group lost at least 10% of body weight, compared with about 12% of the placebo group. Those figures appear in the paper's results tables and are freely viewable in the abstract. More on what Wegovy does and how it works as a once-weekly injection.

What else the PubMed record covers beyond the headline number

STEP 1 is the most cited paper, but the STEP programme published several further trials indexed alongside it. STEP 2 examined semaglutide 2.4mg specifically in adults with type 2 diabetes and found smaller but still meaningful weight reductions, which is consistent with what the research literature shows for GLP-1 medicines in the presence of diabetes. STEP 3 added an intensive behavioural intervention on top; STEP 4 tested what happened when participants stopped semaglutide after 20 weeks, the weight regain data from that paper is frequently cited in discussions about long-term treatment.

The SELECT trial, published in 2023, took a different question to a very large cohort: did semaglutide 2.4mg reduce the risk of serious cardiovascular events in adults with established cardiovascular disease and obesity but without diabetes? It enrolled over 17,500 participants, and the answer, over a median of about 3.3 years, was yes, a 20% relative risk reduction. This evidence contributed to Wegovy receiving a separate UK licence indication for cardiovascular risk reduction, though the primary weight-management licence remains the most relevant for most readers here.

All of these papers are freely searchable on PubMed. The abstracts are open access; full text is often available via the journal's open-access policy or via institutional access.

How NICE translated the PubMed evidence into a recommendation

Published research becomes UK clinical practice when regulators and appraisal bodies work through it. NICE's technology appraisal TA875 reviewed the semaglutide evidence (including the STEP trials) and recommended Wegovy for NHS use in 2023. The criteria are specific: adults with a BMI of 35 or above and at least one weight-related condition, treated for a maximum of two years within a specialist weight management service with multidisciplinary support. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

What that means practically is that the NHS route to Wegovy involves a referral, a wait for a specialist service, and a two-year treatment window. Many people who meet the clinical criteria on paper do not yet have NHS access because of capacity constraints. Private prescribing through a GPhC-registered pharmacy is the alternative route, provided a prescriber assesses you as clinically suitable. The private licensed eligibility criteria broadly mirror the SmPC: BMI 30 or above, or 27 or above with a weight-related condition. Check your eligibility with our clinical team to see whether semaglutide is right for your situation.

What PubMed can and cannot tell you about your own treatment

PubMed is genuinely useful. It gives you the primary data, the trial designs, the adverse event profiles, and the long-term follow-up data, all in one searchable place. The NHS semaglutide medicines page distils the most clinically relevant points for patients in plain language, and it's worth reading alongside the trial abstracts.

What population data cannot do is predict your individual response. Trial averages smooth over a wide range of outcomes; some participants in STEP 1 lost considerably more than 15%, others less. If you are wondering what medicine Wegovy actually is, it is a branded formulation of semaglutide 2.4mg, the same active ingredient studied across the STEP trials. Side effects reported in the trials were predominantly gastrointestinal (nausea, vomiting, diarrhoea, constipation) most common during dose increases and generally settling over time.

Reading PubMed is a good instinct. It means you're approaching this as an informed adult rather than taking a headline at face value. Our overview of semaglutide brings the key evidence together in one place, and if you are ready to get started, you can find full details about Wegovy 1mg doses and how the titration schedule works to help you understand what the early weeks of treatment involve. That's a question for a clinical conversation, not a database search.